Novel therapeutics for the treatment of graft-versus-host disease

Bibliography

• FLOWERS ME, KANSU E, SULLIVAN KM: Pathophysiology and treatment of graft-versus-host disease. Hematol Oncol Clin. North Am. (1999) 13:1091-10ix.
   Google Scholar
• •Excellent basic review of GVHD.
   Google Scholar
• CUTLER C, GIRT S, JEYAPALAN Set al.: Acute and chronic graft-versus-host disease after allogeneic peripheral- blood stem-cell and bone marrow transplantation: a meta-analysis. J. Clin. Omni (2001) 19:3685–3691.
   Google Scholar
• XUN CQ, THOMPSON JS, JENNINGS CD, BROWN SA, WIDMER MB: Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood (1994) 83:2360–2367.
   PubMed Web of Science ®Google Scholar
• CAVENDER DE, HASKARD DO, JOSEPH B, ZIFF M: Interleukin 1 increases the binding of human B and T lymphocytes to endothelial cell monolayers. Immunol (1986) 136:203–207.
   Web of Science ®Google Scholar
• CHANG RJ, LEE SH: Effects of interferon-gamma and tumor necrosis factor-alpha on the expression of an Ia antigen on a murine macrophage cell line." Immunol (1986) 137:2853–2856.
   PubMed Web of Science ®Google Scholar
• LEEUWENBERG JF, VAN DAMME J, MEAGER T, JEUNHOMME TM, BUURMAN WA: Effects of tumor necrosis factor on the interferon-gamma-induced major histocompatibility complex class II antigen expression by human endothelial cells. Eur.j Immunol (1988) 18:1469–1472.
   PubMed Web of Science ®Google Scholar
• POBERJS, GIMBRONE MA, JR., LAPIERRE LA et al: Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor, and immune interferon. Immunol (1986) 137:1893–1896.
   Google Scholar
• THORNHILL MH, WELLICOME SM, MAHIOUZ DL et al.: Tumor necrosis factor combines with IL-4 or IFN-gamma to selectively enhance endothelial cell adhesiveness for T cells. The contribution of vascular cell adhesion molecule-l-dependent and -independent binding mechanisms. I Immunol (1991) 146:592–598.
   Google Scholar
• SETTE A, ALEXANDER J, GREY HM: Interaction of antigenic peptides with MHC and TCR molecules. Clin. ImmunolImmunopathol (1995) 76:S168–S171.
   Web of Science ®Google Scholar
• SAKIHAMA T, SMOLYAR A, REINHERZ EL: Molecular recognition of antigen involves lattice formation between CD4, MHC class II and TCR molecules. Immunol Today (1995) 16:581–587.
   PubMedGoogle Scholar
• FERRARA JL, LEVY R, CHAO NJ: Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol. Blood Marrow Transplant. (1999) 5:347–356.
   PubMedGoogle Scholar
• ••A very detailed overview of thepathophysiology of GVHD.
   Google Scholar
• NESTEL FP, PRICE KS, SEEMAYER TA, LAPP WS: Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J. Exp. Med. (1992) 175:405–413.
   PubMed Web of Science ®Google Scholar
• MOWAT AM: Antibodies to IFN-gamma prevent immunologically mediated intestinal damage in murine graft-versus-host reaction. Immunology (1989) 68:18–23.
   PubMed Web of Science ®Google Scholar
• DICKINSON AM, SVILAND L, DUNN J, CAREY P, PROCTOR SJ: Demonstration of direct involvement of cytokines in graft-versus-host reactions using an M vitro human skin explant model. Bone Marrow Transplant. (1991) 7:209–216.
   PubMed Web of Science ®Google Scholar
• SIMPSON D: Drug therapy for acute graft-versus-host disease prophylaxis. I Hematother. Stem Cell Res. (2000) 9:317–325.
   PubMedGoogle Scholar
• STORB R, DEEG HJ, PEPE M et al.: Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood (1989) 73:1729–1734.
   PubMed Web of Science ®Google Scholar
• •A seminal paper on GVHD prophylaxis.
   Google Scholar
• CHAO NJ, SCHMIDT GM, NILAND JC et al: Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl. I Med. (1993) 329:1225–1230.
   PubMed Web of Science ®Google Scholar
• •A seminal paper on GVHD prophylaxis.
   Google Scholar
• DEEG HJ, LIN D, LEISENRING W et aL: Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. Blood (1997) 89:3880–3887.
   PubMed Web of Science ®Google Scholar
• •A seminal paper on GVHD prophylaxis.
   Google Scholar
• SAYER HG, LONGTON G, BOWDEN R, PEPE M, STORB R: Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft- versus-host disease prevention. Blood (1994) 84:1328–1332.
   PubMed Web of Science ®Google Scholar
• RATANATHARATHORN V, NASH RA, PRZEPIORKA D et al.: Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood (1998) 92:2303–2314.
   PubMed Web of Science ®Google Scholar
• •Important tacrolimus prophylaxis study.
   Google Scholar
• NASH RA, ANTIN JH, KARANES C et al: Phase III study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood (2000) 96:2062–2068.
   PubMed Web of Science ®Google Scholar
• •Important tacrolimus prophylaxis study.
   Google Scholar
• SIGAL NH, DUMONT FJ: Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Ann. Rev. Immunol (1992) 10:519–560.
   PubMed Web of Science ®Google Scholar
• HILL GR, FERRARA JL: The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood (2000) 95:2754–2759.
   PubMed Web of Science ®Google Scholar
• ••Good GVHD pathophyisiology review.
   Google Scholar
• ANTIN JH, LEE SJ, NEUBERG D et al.: A Phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplant. (2002) 29:373–377.
   PubMed Web of Science ®Google Scholar
• LIPSKY JJ: Mycophenolate mofetil. Lancet(1996) 348:1357–1359.
   PubMed Web of Science ®Google Scholar
• Mycophenolate mofetil in cadaveric renal transplantation. US Renal Transplant Mycophenolate Mofetil Study Group. Am. I Kidney Dis. (1999) 34:296–303.
   PubMed Web of Science ®Google Scholar
• BORNHAUSER M, THIEDE C, SCHULER U et al.: Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin. Bone Marrow Transplant. (2000) 26:119–125.
   PubMed Web of Science ®Google Scholar
• LINSLEY PS, BRADY W, URNES M et al.: CTLA-4 is a second receptor for the B cell activation antigen B7. I Exp. Med. (1991) 174:561–569.
   PubMed Web of Science ®Google Scholar
• GUINAN EC, BOUSSIOTIS VA, NEUBERG D et al.: Transplantation of anergic histoincompatible bone marrow allografts. N Engl. J. Med. (1999) 340:1704–1714.
   PubMed Web of Science ®Google Scholar
• ••An important paper on tolerance induction for GVHD prevention.
   Google Scholar
• KIRK AD, BURKLY LC, BATTY DS et al: Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat. Med. (1999) 5:686–693.
   PubMed Web of Science ®Google Scholar
• SEHGAL SN: Rapamune (Sirolimus, rapamycin): an overview and mechanism of action. Ther. Drug Monit. (1995) 17:660–665.
   PubMed Web of Science ®Google Scholar
• LI Y, LI XC, ZHENG XX et al.: Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat. Med. (1999) 5:1298–1302.
   PubMed Web of Science ®Google Scholar
• BENITO Al, FURLONG T, MARTIN PJ et al.: Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation (2001) 72:1924–1929.
   PubMed Web of Science ®Google Scholar
• LUZNIK L, JALLA S, ENGSTROM LW, IANNONE R, FUCHS EJ: Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood (2001) 98:3456–3464.
   PubMed Web of Science ®Google Scholar
• LUZNIK L, ENGSTROM LW, IANNONE R, FUCHS EJ: Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation. Biol. Blood Marrow Transplant. (2002) 8:131–138.
   PubMed Web of Science ®Google Scholar
• ETO M, MAYUMI H, TOMITA Y, YOSHIKAI Y, NOMOTO K: Intrathymic clonal deletion of V beta 6+ T cells in cyclophosphamide- induced tolerance to H-2-compatible, Mls-disparate antigens. I Exp. Med. (1990) 171:97–113.
   PubMed Web of Science ®Google Scholar
• FILIPOVICH AH, VALLERA DA, YOULE RI et al.: Graft-versus-host disease prevention in allogeneic bone marrow transplantation from histocompatible siblings. A pilot study using immunotwdns for T cell depletion of donor bone marrow. Transplantation (1987) 44:62–69.
   Google Scholar
• NOGA SJ, DONNENBERG AD, SCHWARTZ CL et al.: Development of a simplified counterflow centrifugation elutriation procedure for depletion of lymphocytes from human bone marrow. Transplantation (1986) 41:220–229.
   PubMed Web of Science ®Google Scholar
• APPERLEY JF, MAURO FR, GOLDMAN JM et al.: Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect. Br. I Haernatol (1988) 69:239–245.
   PubMed Web of Science ®Google Scholar
• HALE G, COBBOLD S, WALDMANN H: T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation. Transplantation (1988) 45:753–759.
   PubMed Web of Science ®Google Scholar
• COBBOLD S, MARTIN G, WALDMANN H: Monoclonal antibodies for the prevention of graft-versus-host disease and marrow graft rejection. The depletion of T cell subsets in vitro and in vivo. Transplantation (1986) 42:239–247.
   Google Scholar
• HALE G, ZHANG MJ, BUNJES D et al.: Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood (1998) 92:4581–4590.
   PubMed Web of Science ®Google Scholar
• KOTTARIDIS PD, MILLIGAN DW, CHOPRA R et al: ha vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood (2000) 96:2419–2425.
   PubMed Web of Science ®Google Scholar
• RUUTU T, NIEDERWIESER D, GRATWOHL A, APPERLEY IF: A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT. Bone Marrow Transplant. (1997) 19:759–764.
   PubMed Web of Science ®Google Scholar
• HINGS IM, FILIPOVICH AH, MILLER WI et al.: Prednisone therapy for acute graft-versus-host disease: short- versus long-term treatment. A prospective randomized trial. Transplantation (1993) 56:577–580.
   PubMed Web of Science ®Google Scholar
• BACIGALUPO A, VAN LINT MT, FRASSONI F et al.: High dose bolus methylprednisolone for the treatment of acute graft versus host disease. Vat (1983) 46:125–132.
   Google Scholar
• KANOJIA MD, ANAGNOSTOU AA, ZANDER AR et al.: High-dose methylprednisolone treatment for acute graft-versus-host disease after bone marrow transplantation in adults. Transplantation (1984) 37:246–249.
   PubMed Web of Science ®Google Scholar
• VAN LINT MT, UDERZO C, LOCASCIULLI A et al.: Early treatment of acute graft-versus-host disease with high- or low- dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood(1998) 92:2288–2293.
   PubMed Web of Science ®Google Scholar
• DEEG HJ, HENSLEE-DOWNEY PJ: Management of acute graft-versus-host disease. Bone Marrow Transplant. (1990) 6:1–8.
   PubMed Web of Science ®Google Scholar
• MARGOLIS J, DAVIDSON R, DOHERTY J, ALTOMONTE V, VOGELSANG G: Poor outcome in steroid refractory GVHD with ATG treatment. Blood (1999) 94:152a. Abstract.
   Google Scholar
• PRZEPIORKA D, PHILLIPS GL, RATANATHARATHORN V et al.: A Phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. Blood (1998) 92:4066–4071.
   PubMed Web of Science ®Google Scholar
• MCCARTHY PL, JR., WILLIAMS L, HARRIS-BACILE M et al.: A clinical Phase I/II study of recombinant human interleukin-1 receptor in glucocorticoid-resistant graft-versus-host disease. Transplantation (1996) 62:626–631.
   Google Scholar
• CAHN JY, BORDIGONI P, TIBERGHIEN P et al.: Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter Phase III study. Transplantation (1995) 60:939–942.
   PubMed Web of Science ®Google Scholar
• ANASETTI C, LIN A, NADEMANEE A et al.: A Phase II/III randomized, double-blind, placebo-controlled multicenter trial of humanized anti-TAC for prevention of acute graft-versus-host disease (GVHD) in recepients of marrow transplantation from unrelated donors. Blood (1995) 86:621a-
   Google Scholar
• QUEEN C, SCHNEIDER WP, SELICK HE et al.: A humanized antibody that binds to the interleukin 2 receptor. Proc. Nati Acad. Sci. USA (1989) 86:10029–10033.
   PubMed Web of Science ®Google Scholar
• JUNGHANS RP, WALDMANN TA, LANDOLFI NF et al.: Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res. (1990) 50:1495–1502.
   PubMed Web of Science ®Google Scholar
• PRZEPIORKA D, KERNAN NA, IPPOLITI C et al.: Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood (2000) 95:83–89.
   PubMed Web of Science ®Google Scholar
• COURIEL DR, HICKS K, GIRALT S, CHAMPLIN RE: Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation. Carr. Opin. Oncol (2000) 12:582–587.
   PubMed Web of Science ®Google Scholar
• MARGOLIS J, JACOBSOHN D, PHELPS M et al.: Pentostatin: A novel treatment for steroid refractory acute GVHD. Blood (2000) 96:400a. Abstract.
   Google Scholar
• KOCH C, STAFFLER G, HUTTINGER R et al.: T cell activation-associated epitopes of CD147 in regulation of the T cell response, and their definition by antibody affinity and antigen density. hat. bronunol (1999) 11:777–786.
   Google Scholar
• KINUKAWA T, TERASAKI PI: Clonal deletion by a monoclonal antiblast antibody following primary mixed lymphocyte culture. Transplant. Proc. (1985) 17:993–998.
   Web of Science ®Google Scholar
• DEEG HJ, BLAZAR BR, BOLWELL BJ et al.: Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood (2001) 98:2052–2058.
   PubMed Web of Science ®Google Scholar
• COLE MS, STELLRECHT KE, SHI JD et al: HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro. Transplantation (1999) 68:563–571.
   PubMed Web of Science ®Google Scholar
• CARPENTER PA, PAVLOVIC S, TSO JY et al.: Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells." hallnunol (2000) 165:6205–6213.
   Google Scholar
• CARPENTER PA, APPELBAUM FR, COREY L et al.: A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood (2002) 99:2712-2719. bone marrow transplantation. Blood (1989) 74:1428–1435.
   Google Scholar
• SULLIVAN KM, WITHERSPOON RP, STORB R et al.: Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood (1988) 72:555–561.
   PubMed Web of Science ®Google Scholar
• •A seminal paper on chronic GVHD therapy.
   Google Scholar
• WINGARD JR, PIANTADOSI S, VOGELSANG GB et al: Predictors of death from chronic graft-versus-host disease after bone marrow transplatation. Blood (1989) 74:1428–1435.
   PubMed Web of Science ®Google Scholar
• PARKER PM, CHAO N, NADEMANEE A et al: Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood (1995) 86:3604–3609.
   PubMed Web of Science ®Google Scholar
• VOGELSANG GB, FARMER ER, HESS AD et al: Thalidomide for the treatment of chronic graft-versus-host disease. N Engl. J. Med. (1992) 326:1055–1058.
   PubMed Web of Science ®Google Scholar
• SULLIVAN KM, WITHERSPOON RP, STORB R et al.: Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood (1988) 72:546–554.
   PubMed Web of Science ®Google Scholar
• MOOKERJEE B, ALTOMONTE V, VOGELSANG G: Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. Bone Marrow Transplant. (1999) 24:517–520.
   PubMed Web of Science ®Google Scholar
• JACOBSOHN DA, MARGOLIS J, CHEN AR et al.: Pentostatin: a promising treatment for refractory chronic GVHD. Blood (1 A.D.) 98:399a. Abstract.
   Google Scholar
• MARCELLUS DC, ALTOMONTE VL, FARMER ER et al.: Etretinate therapy for refractory sclerodermatous chronic graft-versus- host disease. Blood(1999) 93:66–70.
   PubMed Web of Science ®Google Scholar
• LEE SJ, WEGNER SA, MCGARIGLE CJ, BIERER BE, ANTIN JH: Treatment of chronic graft-versus-host disease with clofazimine. Blood (1997) 89:2298–2302.
   PubMed Web of Science ®Google Scholar
• GILMAN AL, CHAN KW, MOGUL A et al: Hydroxychloroquine for the treatment of chronic graft-versus-host disease. Biol. Blood Marrow Transplant. (2000) 6:327–334.
   PubMed Web of Science ®Google Scholar
• VOGELSANG GB, WOLFF D, ALTOMONTE V et al.: Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA). Bone Marrow Transplant. (1996) 17:1061–1067.
   PubMed Web of Science ®Google Scholar
• AUBIN F, BRION A, DECONINCK E et al.: Phototherapy in the treatment of cutaneous graft-versus-host disease. Our preliminary experience in resistant patients. Transplantation (1995) 59:151–155.
   Google Scholar
• GREINIX HT, VOLC-PLATZER B, RABITSCH W et al: Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood (1998) 92:3098–3104.
   PubMed Web of Science ®Google Scholar
• PRZEPIORKA D, WEISDORF D, MARTIN P et al.: 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. (1995) 15:825–828.
   PubMed Web of Science ®Google Scholar
• •Discusses the current acute GVHD grading scale.
   Google Scholar
• WIESNETH M, HERTENSTEIN B, BUNJES D et al.: T-cell depletion versus methotrexate as GvHD-prophylaxis in allogeneic bone marrow transplantation for leukaemia. Ear: J. Haematol. (1988) 41:243–249.
   PubMed Web of Science ®Google Scholar
• TAYLOR PA, LEES CJ, BLAZAR BR: The infusion of ex vivo activated and expanded CD4+CD25+ immune regulatory cells inhibits graft-versus-host disease lethality. Blood (2002) 99:3493–3499.
   PubMed Web of Science ®Google Scholar